Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $207,118.36 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) COO Adrian Haigh sold 22,223 shares of the firm's stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $9.32, for a total transaction of $207,118.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Adrian Haigh also recently made the following trade(s):

• On Friday, April 19th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.34, for a total transaction of $207,553.48.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.91, for a total transaction of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.30, for a total transaction of $228,886.60.

Fennec Pharmaceuticals Stock Performance

Shares of Fennec Pharmaceuticals stock traded up $0.04 during trading on Monday, hitting $9.38. 164,514 shares of the company's stock were exchanged, compared to its average volume of 111,914. The business has a 50-day simple moving average of $10.07 and a 200-day simple moving average of $9.38. Fennec Pharmaceuticals Inc has a 52-week low of $6.30 and a 52-week high of $11.92. The stock has a market capitalization of $254.20 million, a price-to-earnings ratio of -15.38 and a beta of 0.38.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.12). The business had revenue of $9.74 million for the quarter, compared to the consensus estimate of $9.47 million. On average, equities analysts anticipate that Fennec Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FENC. Worth Venture Partners LLC grew its stake in Fennec Pharmaceuticals by 52.7% during the 4th quarter. Worth Venture Partners LLC now owns 141,500 shares of the company's stock valued at $1,588,000 after acquiring an additional 48,864 shares in the last quarter. AIGH Capital Management LLC grew its stake in Fennec Pharmaceuticals by 6.9% during the 3rd quarter. AIGH Capital Management LLC now owns 373,526 shares of the company's stock valued at $2,805,000 after acquiring an additional 24,069 shares in the last quarter. Eudaimonia Advisors LLC grew its stake in Fennec Pharmaceuticals by 90.8% during the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company's stock valued at $367,000 after acquiring an additional 15,556 shares in the last quarter. Jump Financial LLC purchased a new stake in Fennec Pharmaceuticals during the 4th quarter valued at about $158,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Fennec Pharmaceuticals during the 3rd quarter valued at about $50,000. Hedge funds and other institutional investors own 55.51% of the company's stock.

Analysts Set New Price Targets

FENC has been the subject of several research reports. Craig Hallum lifted their price objective on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a research note on Monday, March 18th. HC Wainwright raised their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Thursday, April 4th. Finally, Wedbush reissued an "outperform" rating and set a $16.00 target price on shares of Fennec Pharmaceuticals in a report on Monday, March 18th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.